



Article in early access

Articles in early access are accepted and revised articles that have not yet passed the editing, pagination and proofreading, but they can be cited (see below). When the final version of the article is available the early access version will be removed.

Note: the editing, pagination and proofreading process may lead to differences between the in press and final versions.

How to cite:

Ferreira, G., Afreixo, V., Iutis, A., & Silva, R. (2022). Meta-analysis of Chemical exposure and increased risk of hematologic malignancies. *Journal of Statistics on Health Decision*, 4(2), e24961.

<https://doi.org/10.34624/jshd.v4i2.24961>

Published online: December 30, 2022.

Meta-analysis of Chemical exposure and increased risk of hematologic malignancies.

Ferreira, G., Afreixo, V., Iutis, A., & Silva, R.

1 **Meta-analysis of Chemical exposure and increased risk of hematologic**
2 **malignancies.**

3 Gisela Ferreira^{1,2}, Vera Afreixo³, Adela Iutis⁴, Raquel M Silva^{2,5}

4 ¹ Centro Hospitalar do Baixo Vouga, EPE, Aveiro, Portugal

5 ² Department of Medical Sciences & iBiMED-Institute of Biomedicine, University of
6 Aveiro, Aveiro, Portugal

7 ³ Department of Mathematics, CIDMA & iBiMED, University of Aveiro, Aveiro, Portugal

8 ⁴ Department of Mathematics, University of Aveiro, Aveiro, Portugal

9 ⁵ Universidade Católica Portuguesa, Faculdade de Medicina Dentária, Centro de
10 Investigação Interdisciplinar em Saúde, Viseu, Portugal

11
12 **Correspondence to:** Raquel M. Silva

13 Universidade Católica Portuguesa, Faculdade de Medicina Dentária

14 Estrada da Circunvalação, 3504-505 Viseu, Portugal

15 rmsilva@ucp.pt

16
17 **Disclosures**

18 The authors declare no conflict of interest.

19 This research did not receive any specific grant from funding agencies in the public,
20 commercial, or not-for-profit sectors.

21
22
23 **Meta-analysis of Chemical exposure and increased risk of hematologic**
24 **malignancies.**

25 **Abstract**

26 **Background:** Exposure to environmental risk factors may be associated with the
27 development of hematologic malignancies, as pointed by evidence in the literature.

28 Despite this, most studies refer to a specific risk factor or disease.

29 **Objective:** To assess this issue globally, in this study we performed a meta-analysis.

30 **Methods:** A searched PubMed database was done in 2020 and a selection of 35 case-
31 control and cohort studies published between 1990 and 2020 was done.

32 **Results:** Was observed a significant adverse association between exposure to organic
33 solvents such as benzene and incidence of myeloid malignancies. For agricultural

34 chemicals (pesticides, herbicides, insecticides), an adverse association was found for
35 both lymphoid and myeloid malignancies.

36 **Conclusions:** The results suggest that activities in chemical industries or agriculture
37 pose greater risk and should be closely monitored. Prospective occupational surveys
38 are needed to identify exposure–response relationships and clarify disease
39 mechanisms.

40

41 **Keywords:** lymphoid; myeloid; risk; benzene; agriculture; smoking; indoor tanning; paint.

42

43 **Introduction**

44 Occupational and lifestyle-related exposures have been suggested as risk factors for
45 the development of a multitude of hematologic malignancies. Generally, the
46 associations tend to increase with longer duration of exposure, so that prolonged
47 follow-ups are usually necessary to validate the exposure-outcome relationship [1].
48 Hematologic malignancies are characterized by the proliferation of clonal mature or
49 immature cells, either myeloid or lymphoid, that tend to have a proliferative advantage
50 opposed to the normal counterpart [2].

51 Chemicals that have been implicated in these diseases include organochlorines and
52 phenoxyacetic acids that are commonly found in pesticides and herbicides [3-6]. For
53 these compounds, in addition to occupational exposure there is a risk of consumption
54 of contaminated food and drinking water [7]. Among environmental exposures, high-
55 level benzene exposure is accepted as a cause of chromosome damage and acute
56 leukemia (AL) [8-10]. Benzene's toxicity is related to cumulative dosage, and the risk of
57 AL and myelodysplastic syndromes (MDS) was high before current occupational safety
58 standards [11, 12].

59 In what concerns lifestyle-related exposures, cigarette smoking was linked to a small
60 increase in risk for acute lymphoblastic leukemia (ALL) among adults [13]. In other two

61 reports, smoking was found to be a risk factor for acute myeloid leukemia (AML) and
62 MDS [14, 15]. In addition, there are epidemiologic studies that implicate indoor tanning
63 in the development of non-Hodgkin Lymphomas (NHL) [16, 17], however, this
64 association was refuted by others [18, 19].

65 In the literature, specific jobs and hobbies that are related with an increased risk for the
66 development of AML include those manufacturing or exposed to paint or hair dyes [13].

67 A number of other factors have been mentioned, including ionizing radiation,
68 electromagnetic fields, or alcohol, to name a few, but the data is weak to support an
69 association of any of these factors with an increased risk of hematologic neoplasms
70 [20-23].

71 Although the evidence suggests an association between chemical exposures and
72 hematologic malignancies, data is dispersed in the literature and many studies are
73 focused on single risk factors, in individual diseases or a specific group of diseases.

74 Here, to assess potential associations between exposure to a variety of environmental
75 factors and the risk of developing hematologic neoplasms, we performed a meta-
76 analysis.

77

78 **Methods and Statistical analysis**

79 *Literature search*

80 A literature search was performed in PubMed on the 16th of May 2019, with the
81 keywords “risk factor and cancer and hematologic and (chemical OR pollution OR air
82 OR water OR environmental) NOT childhood” with the filter language=“English”
83 activated, and 592 abstracts were retrieved. The same search was repeated in May
84 2020, and 73 additional abstracts were screened to determine the suitability of each
85 publication.

86 Of the total 665 works, 595 were excluded because they focused on secondary
87 cancers or mentioned consequences and not causes of the cancer, such as

88 microbiological infections in cancer patients; others had no environmental risk factors
89 associated or were not about cancer but rather about hematologic alterations in other
90 diseases; some were performed in animal models, referred to solid cancers, to the
91 paediatric population, or were reviews. For the remaining 70 works, the full-text articles
92 were considered, and further 35 were excluded because there were no suitable data
93 (either no cases, controls, or environmental data) (Figure 1).

94 *Study selection*

95 Studies included in this meta-analysis [3-6, 9, 10, 12-14, 18-43] had to meet all the
96 following criteria: (a) the exposures of interest were chemical (benzene, other
97 solvents), agricultural (pesticide, herbicide) and lifestyle (smoking, paint, indoor
98 tanning); (b) the outcomes of interest were incidence of hematologic malignancies; (c)
99 a cohort design or case-control design; (d) provide the risk and corresponding 95%
100 confidence intervals (CIs) or data to calculate these. If there were multiple publications
101 from the same study or overlapping study populations, the most recent and detailed
102 study was eligible for inclusion in the meta-analysis. Details of the selected studies are
103 provided in Table 1.

104 *Data extraction*

105 Data were collected independently by two authors using a predefined data collection
106 form. The following data were extracted from each study and included in the final
107 analysis: the study name (the first author's name and year of publication), country of
108 origin, gender, age, study design, source of patients, number of cases/controls, risk
109 factor assessment, matching covariates, and adjusted covariates. When necessary, the
110 corresponding authors of the primary studies were contacted to obtain missing or
111 insufficient data, and group consensus was used to resolve discrepancies.

112 *Statistical analysis*

113 When present, all within-study effect sizes were aggregated with agg function from
114 MAD package (agg: Aggregate Dependent Effect Sizes,

115 <https://rdrr.io/cran/MAd/man/agg.html>), while considering the correlations among the
116 within-study outcomes).

117 To determine whether to use the fixed- or random-effects model, we measured
118 statistical heterogeneity. A fixed-effects model was used to calculate a pooled odds
119 ratio (OR) with 95% CI when there was no heterogeneity. Otherwise, we calculated
120 pooled ORs and confidence intervals assuming a random-effects model. The
121 heterogeneity of ORs across individual studies was quantified by the Q statistic and the
122 I² score. $P > 0.1$ for the Q-test was considered as a lack of heterogeneity among the
123 studies. The I² values of 25%, 50%, and 75% represented mild, moderate, and severe
124 heterogeneity, respectively [44].

125 Potential publication bias was assessed by using Begg's funnel plots (rank correlation
126 method where an asymmetrical plot suggested possible publication bias) [45] and
127 Begg's bias test (a strong correlation implies publication bias $P < 0.05$ indicated the
128 presence of statistically significant publication bias) [46] and by calculating the 'fail-safe
129 N', the number of additional 'negative' studies (studies in which the intervention effect
130 was zero) that would be needed to increase the P value for the meta-analysis to above
131 0.05.

132 Sensitivity analysis was conducted, in which the meta-analysis estimates were
133 calculated by sequential omission of every study in turn, so as to reflect the influence of
134 the data from individual studies on the pooled ORs and evaluate the stability of the
135 results. Subset analyses were performed by cell lineage type. All the statistical
136 analyses were performed using software R version 3.6.1 © 2019, in RStudio
137 environment Version 1.2.1578© 2009-2019 R Studio, Inc., where $P < 0.05$ was
138 considered statistically significant.

139

140 **Results**

141 A total of 35 case-control and cohort studies were included in the present work, on the
142 association of agriculture, chemical and lifestyle exposures with the incidence of
143 hematologic malignancies. These studies were published between 1990 and 2020 and
144 were conducted in Europe, Asia and in the United States.

145

146 *Risk estimation*

147 Our analyses demonstrated a significant adverse association between agriculture and
148 chemical exposures (exposed vs. non-exposed status) and incidence of hematologic
149 malignancies. The results for agriculture exposure (OR = 1.48, 95%CI 1.26–1.74) are
150 shown in Figure 2, and for chemical exposure (OR = 1.75, 95%CI 1.15–2.28) are
151 presented in Figure 3. A statistically significant heterogeneity across studies was
152 observed, for agriculture exposure ($I^2 = 85\%$, $P < 0.01$) and for chemical exposure ($I^2 =$
153 80% , $P < 0.01$), and the summary OR were estimated using the random effects model.

154

155 *Stratified analysis*

156 We pooled the OR estimates of hematologic malignancies according to the cell type
157 (lymphoid and myeloid lineage) and for each group of exposure (agriculture, chemical
158 and lifestyle exposures). In this subset analyses, a statistically significant adverse
159 effect of agriculture exposure on hematologic malignancies was observed for both
160 lymphoid (OR = 1.38, 95%CI 1.11-1.72) and myeloid (OR = 1.79, 95%CI 1.28-2.50)
161 disease groups. For the chemical exposure, a statistically significant adverse effect
162 was observed for the myeloid diseases (OR = 2.15, 95%CI 1.63-2.85). In the lifestyle
163 exposure group, a significant adverse effect was observed between smoking and
164 incidence of myeloid diseases (OR = 2.45, 95%CI 1.61-3.73), which was not observed
165 in paint and indoor tanning exposures (Table 2).

166

167 *Publication bias*

168 As reflected by the funnel plot (not shown), Begg's test, no asymmetry was discovered
169 for agriculture (Begg's test, $P = 0.175$), chemical (Begg's test, $P = 0.272$), smoking
170 (Begg's test, $P = 0.188$), paint (Begg's test, $P = 0.09$), or indoor tanning (Begg's test, P
171 $= 0.051$).

172

173 *Sensitivity analysis*

174 We also carried out sensitivity analysis by sequentially excluding one study at a time to
175 detect the influence of a single study on the overall estimate. The results demonstrated
176 that no study disproportionately affected the summary risk estimates in this meta-
177 analysis. The study-specific ORs were 1.34 (95%CI 1.27-1.40) for agriculture, 1.15
178 (95%CI 1.02-1.30) for chemical, 1.03 (95%CI 0.91-1.18) for smoking, 1.12 (95%CI
179 0.98-1.27) for paint and 1.01 (95%CI 0.80-1.27) for indoor tanning.

180

181 **Discussion**

182 Indoor and outdoor pollution has been associated with both acute and chronic human
183 health conditions, including cancer [7]. We attempted to clarify the possible relationship
184 between exposure to chemicals and the risk of developing hematologic malignancies,
185 through a meta-analysis of case-control and cohort studies.

186 The results showed a significant adverse effect of the exposure to chemical
187 compounds used in agriculture and hematologic malignancies. We also demonstrated
188 a significant adverse association between exposure to benzene and other organic
189 solvents. Regarding lifestyle exposures, the effect was observed in smoking but not in
190 paint and indoor tanning groups. Our results are consistent with previous findings [19,
191 47, 48] but should be interpreted with caution, as there are some limitations in the
192 present study. Since we have considered several studies within a timeframe of 30
193 years (1990-2020), it can be speculated that enforcement of regulations involving
194 occupational exposures has altered the occupational risk profile. On the other hand, we

195 also considered studies with small sample size. By doing this meta-analysis we
196 increased sample size and validated our findings with diverse populations.
197 Finally, one can argue that there is probably a lack of data consistency, which could
198 compromise the ability to pool data in a standardized form. The designations of the
199 different hematologic diseases, as well as their diagnosis, have changed through time,
200 and some authors do not specify which disease is considered in each study. In order to
201 overcome that, we have included several diseases in the same group, according to the
202 cell lineage from which they are originated (either lymphoid or myeloid). The use of
203 data from distinct geographical regions may also contribute to heterogeneity, and the
204 fact that we could observe associations between environmental risk factors and
205 hematologic malignancies, in spite these limitations, strengthens the approach and the
206 results obtained.

207 As discussed previously, the great majority of the epidemiologic studies here
208 considered are observational ones. This prevents the establishment of causal
209 mechanisms between exposure variables and responses of interest.

210 Epidemiologic studies are often flawed because of small sample size and retrospective
211 nature. In fact, there is a clear lack of carefully designed prospective epidemiologic
212 studies, with large cohorts and prolonged follow-up, able to determine the validity of an
213 association between a factor and a specific hematologic malignancy. As such,
214 prospective planning of epidemiologic studies prior to any data collection is crucial to
215 study accuracy. It would be interesting to perform a prospective national occupational
216 survey and identify exposure–response relationships. This would allow to 1) better
217 understand the underlying disease mechanisms triggered by the environment and,
218 ultimately, 2) diminish their occurrence in the first place.

219

220 **Acknowledgements**

221 This work was supported by FEDER and FCT (“Fundação para a Ciência e a
222 Tecnologia”), within the research unit funding UIDB/04501/2020 (POCI-01-0145-
223 FEDER-007628) to iBiMED, UID/MAT/04106/2013 to CIDMA, and UIDB/04279/2020
224 and UIDP/04279/2020 to CIIS. Thanks are due to FCT/MCTES and UCP for the CEEC
225 institutional funding of RMS.

226 **Author contributions:**

227 Conceptualization: GF, VA, RMS. Data curation: GF, AI, RMS. Formal analysis: VA, AI.
228 Methodology: VA, AI, RMS. Project administration: VA, RMS. Visualization: AI. Writing
229 – original draft: GF, AI. Writing – review & editing: GF, VA, AI, RMS.

230

231 **References**

- 232 1. Descatha A, Jenabian A, Conso F and Ameille J. Occupational exposures and
233 haematological malignancies: overview on human recent data. *Cancer Causes
234 Control* 2005;16:939-53.
- 235 2. Harris NL, Jaffe ES, Diebold J, Flandrin G, Muller-Hermelink HK, Vardiman J, et
236 al. World Health Organization classification of neoplastic diseases of the
237 hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee
238 meeting-Airlie House, Virginia, November 1997. *J Clin Oncol* 1999;17:3835-49.
- 239 3. Nisse C, Haguenoer JM, Grandbastien B, Preudhomme C, Fontaine B, Brillet JM
240 et al. Occupational and environmental risk factors of the myelodysplastic
241 syndromes in the North of France. *Br J Haematol* 2001;112:927-35.
- 242 4. Rigolin GM, Cuneo A, Roberti MG, Bardi A, Bigoni R, Piva N, et al. Exposure to
243 myelotoxic agents and myelodysplasia: case-control study and correlation with
244 clinicobiological findings. *Br J Haematol* 1998;103:189-97.
- 245 5. Ciccone G, Mirabelli D, Levis A, Gavarotti P, Rege-Cambrin G, Davico L et al.
246 Myeloid leukemias and myelodysplastic syndromes: chemical exposure,
247 histologic subtype and cytogenetics in a case-control study. *Cancer Genet*

- 248 Cytogenet 1993;68:135-9.
- 249 6. Kokouva M, Bitsolas N, Hadjigeorgiou GM, Rachiotis G, Papadoulis N and
250 Hadjichristodoulou C. Pesticide exposure and lymphohaematopoietic cancers: a
251 case-control study in an agricultural region (Larissa, Thessaly, Greece). BMC
252 Public Health 2011;11:5.
- 253 7. World Health Organization (WHO). Preventing disease through healthy
254 environments: exposure to benzene: a major public health concern.
255 2019;<https://apps.who.int/iris/handle/10665/329481>.
- 256 8. Strom SS, Oum R, Elhor Gbito KY, Garcia-Manero G and Yamamura Y. De
257 novo acute myeloid leukemia risk factors: a Texas case-control study. Cancer
258 2012;118:4589-96.
- 259 9. Teras LR, Diver WR, Deubler EL, Krewski D, Flowers CR, Switchenko JM et al.
260 Residential ambient benzene exposure in the United States and subsequent risk
261 of hematologic malignancies. Int J Cancer 2019;145:2647-2660.
- 262 10. Hayes RB, Yin SN, Dosemeci M, Li GL, Wacholder S, Travis LB et al. Benzene
263 and the dose-related incidence of hematologic neoplasms in China. Chinese
264 Academy of Preventive Medicine--National Cancer Institute Benzene Study
265 Group. J Natl Cancer Inst 1997; 89:1065-71.
- 266 11. Schnatter AR, Glass DC, Tang G, Irons RD and Rushton L. Myelodysplastic
267 syndrome and benzene exposure among petroleum workers: an international
268 pooled analysis. J Natl Cancer Inst 2012;104:1724-37.
- 269 12. Poynter JN, Richardson M, Roesler M, Blair CK, Hirsch B, Nguyen P et al.
270 Chemical exposures and risk of acute myeloid leukemia and myelodysplastic
271 syndromes in a population-based study. Int J Cancer 2017;140:23-33.
- 272 13. Mele A, Szklo M, Visani G, Stazi MA, Castelli G, Pasquini P et al. Hair dye use
273 and other risk factors for leukemia and pre-leukemia: a case-control study.
274 Italian Leukemia Study Group. Am J Epidemiol 1994;139:609-19.

- 275 14. Strom SS, Gu Y, Gruschkus SK, Pierce SA and Estey EH. Risk factors of
276 myelodysplastic syndromes: a case-control study. *Leukemia* 2005;19:1912-8.
- 277 15. Wang P, Liu H, Jiang T and Yang J. Cigarette Smoking and the Risk of Adult
278 Myeloid Disease: A Meta-Analysis. *PLoS One* 2015;10:e0137300.
- 279 16. Chang ET, Canchola AJ, Cockburn M, Lu Y, Wang SS, Bernstein L et al.
280 Adulthood residential ultraviolet radiation, sun sensitivity, dietary vitamin D, and
281 risk of lymphoid malignancies in the California Teachers Study. *Blood*
282 2011;118:1591-9
- 283 17. Bertrand KA, Chang ET, Abel GA, Zhang SM, Spiegelman D, Qureshi AA et al.
284 Sunlight exposure, vitamin D, and risk of non-Hodgkin lymphoma in the Nurses'
285 Health Study. *Cancer Causes Control* 2011;22:1731-41.
- 286 18. Wang SS, Luo J, Cozen W, Lu Y, Halley-Sullivan J, Voutsinas J et al. Sun
287 sensitivity, indoor tanning and B-cell non-Hodgkin lymphoma risk among
288 Caucasian women in Los Angeles County. *Br J Haematol* 2017;177:153-156.
- 289 19. Zhang M, Song F, Hunter DJ, Qureshi AA and Han J. Tanning bed use is not
290 associated with internal cancer risk: evidence from a large cohort study. *Cancer*
291 *Epidemiol Biomarkers Prev* 2013;22:2425-9.
- 292 20. Boffetta P, van der Hel O, Krickler A, Nieters A, de Sanjosé S, Maynadié M et al.
293 Exposure to ultraviolet radiation and risk of malignant lymphoma and multiple
294 myeloma--a multicentre European case-control study. *Int J Epidemiol*
295 2008;37:1080-94.
- 296 21. Zhang Y, Holford TR, Leaderer B, Boyle P, Zhu Y, Wang R et al. Ultraviolet
297 radiation exposure and risk of non-Hodgkin's lymphoma. *Am J Epidemiol*
298 2007;165:1255-64.
- 299 22. Wehkopf T, Becker N, Nieters A, Mester B, Deeg E, Elsner G et al. Sun
300 exposure and malignant lymphoma: a population-based case-control study in
301 Germany. *Int J Cancer* 2007;120:2445-51.

- 302 23. Hartge P, Lim U, Freedman DM, Colt JS, Cerhan JR, Cozen W et al. Ultraviolet
303 radiation, dietary vitamin D, and risk of non-Hodgkin lymphoma (United States).
304 *Cancer Causes Control* 2006;17:1045-52.
- 305 24. Wang SS, Flowers CR, Kadin ME, Chang ET, Hughes AM, Ansell SM et al.
306 Medical history, lifestyle, family history, and occupational risk factors for
307 peripheral T-cell lymphomas: the InterLymph Non-Hodgkin Lymphoma Subtypes
308 Project. *J Natl Cancer Inst Monogr* 2014;2014:66-75.
- 309 25. Zhang J, Ye X, Wu C, Fu H, Xu W and Hu P. Modeling Gene-Environment
310 Interaction for the Risk of Non-hodgkin Lymphoma. *Front Oncol* 2018;8:657.
- 311 26. Ben-Eli H, Aframian DJ, Ben-Chetrit E, Mevorach D, Kleinstern G, Paltiel O et al.
312 Shared Medical and Environmental Risk Factors in Dry Eye Syndrome,
313 Sjogren's Syndrome, and B-Cell Non-Hodgkin Lymphoma: A Case-Control
314 Study. *J Immunol Res* 2019;2019:9060842
- 315 27. Heavner K, Gross-Davis CA, Frank AL, Newschaffer C, Klotz J and Burstyn I.
316 Working environment and myeloproliferative neoplasm: A population-based
317 case-control study following a cluster investigation. *Am J Ind Med* 2015;58:595-
318 604.
- 319 28. Benavente Y, Casabonne D, Costas L, Robles C, Alonso E, de la Banda E et al.
320 Established and suggested exposures on CLL/SLL etiology: Results from the
321 CLL-MCC-Spain study. *Cancer Epidemiol* 2018;52:106-111.
- 322 29. Morton LM, Slager SL, Cerhan JR, Wang SS, Vajdic CM, Skibola CF, et al.
323 Etiologic heterogeneity among non-Hodgkin lymphoma subtypes: the
324 InterLymph Non-Hodgkin Lymphoma Subtypes Project. *J Natl Cancer Inst*
325 *Monogr* 2014;2014:130-44.
- 326 30. Fan R, Zhang LY, Wang H, Yang B, Han T, Zhao XL et al. Multicentre hospital-
327 based case-control study of diffuse large B-cell lymphoma in Shanghai, China.
328 *Asian Pac J Cancer Prev* 2012;13:3329-34.

- 329 31. Veierød MB, Smedby KE, Lund E, Adami HO and Weiderpass E. Pigmentary
330 characteristics, UV radiation exposure, and risk of non-Hodgkin lymphoma: a
331 prospective study among Scandinavian women. *Cancer Epidemiol Biomarkers*
332 *Prev* 2010;19:1569-76.
- 333 32. Kelly JL, Friedberg JW, Calvi LM, van Wijngaarden E and Fisher SG. A case-
334 control study of ultraviolet radiation exposure, vitamin D, and lymphoma risk in
335 adults. *Cancer Causes Control* 2010;21:1265-75.
- 336 33. Brown LM, Blair A, Gibson R, Everett GD, Cantor KP, Schuman LM, et al.
337 Pesticide exposures and other agricultural risk factors for leukemia among men
338 in Iowa and Minnesota. *Cancer Res* 1990;50:6585-91.
- 339 34. Goldberg H, Lusk E, Moore J, Nowell PC and Besa EC. Survey of exposure to
340 genotoxic agents in primary myelodysplastic syndrome: correlation with
341 chromosome patterns and data on patients without hematological disease.
342 *Cancer Res* 1990;50:6876-81.
- 343 35. Lv L, Lin G, Gao X, Wu C, Dai J, Yang Y et al. Case-control study of risk factors
344 of myelodysplastic syndromes according to World Health Organization
345 classification in a Chinese population. *Am J Hematol* 2011;86:163-9.
- 346 36. West RR, Stafford DA, Farrow A and Jacobs A. Occupational and environmental
347 exposures and myelodysplasia: a case-control study. *Leuk Res* 1995;19:127-39.
- 348 37. Costas L, Infante-Rivard C, Zock JP, Van Tongeren M, Boffetta P, Cusson A et
349 al. Occupational exposure to endocrine disruptors and lymphoma risk in a multi-
350 centric European study. *Br J Cancer* 2015;112:1251-6.
- 351 38. Grandin L, Orsi L, Troussard X, Monnereau A, Berthou C, Fenaux P et al. UV
352 radiation exposure, skin type and lymphoid malignancies: results of a French
353 case-control study. *Cancer Causes Control* 2008;19:305-15.
- 354 39. Pekmezovic T, Suvajdzic Vukovic N, Kistic D, Grgurevic A, Bogdanovic A, Gotic
355 M et al. A case-control study of myelodysplastic syndromes in Belgrade (Serbia

- 356 Montenegro). *Ann Hematol* 2006;85:514-9.
- 357 40. Slager SL, Benavente Y, Blair A, Vermeulen R, Cerhan JR, Costantini AS et al.
358 Medical history, lifestyle, family history, and occupational risk factors for chronic
359 lymphocytic leukemia/small lymphocytic lymphoma: the InterLymph Non-
360 Hodgkin Lymphoma Subtypes Project. *J Natl Cancer Inst Monogr* 2014;2014:41-
361 51.
- 362 41. Smedby KE, Hjalgrim H, Melbye M, Torr ang A, Rostgaard K, Munksgaard L et
363 al. Ultraviolet radiation exposure and risk of malignant lymphomas. *J Natl*
364 *Cancer Inst* 2005;97:199-209.
- 365 42. Smedby KE, Sampson JN, Turner JJ, Slager SL, Maynadi  M, Roman E et al.
366 Medical history, lifestyle, family history, and occupational risk factors for mantle
367 cell lymphoma: the InterLymph Non-Hodgkin Lymphoma Subtypes Project. *J*
368 *Natl Cancer Inst Monogr* 2014;2014:76-86.
- 369 43. Stenehjem JS, Kj rheim K, Br tveit M, Samuelsen SO, Barone-Adesi F,
370 Rothman N et al. Benzene exposure and risk of lymphohaematopoietic cancers
371 in 25,000 offshore oil industry workers. *Br J Cancer* 2015;113:1641.
- 372 44. Higgins JP, Thompson SG, Deeks JJ and Altman DG. Measuring inconsistency
373 in meta-analyses. *BMJ* 2003;327:557-60.
- 374 45. Begg CB and Mazumdar M. Operating characteristics of a rank correlation test
375 for publication bias. *Biometrics* 1994;50:1088-101.
- 376 46. Egger M, Davey Smith G, Schneider M and Minder C. Bias in meta-analysis
377 detected by a simple, graphical test. *BMJ* 1997;315:629-34.
- 378 47. O'Sullivan DE, Hillier TWR, Brenner DR, Peters CE and King WD. Indoor
379 tanning and the risk of developing non-cutaneous cancers: a systematic review
380 and meta-analysis. *Cancer Causes Control* 2018;29:937-950.
- 381 48. Jin J, Yu M, Hu C, Ye L, Xie L, Chen F et al. Pesticide exposure as a risk factor
382 for myelodysplastic syndromes: a meta-analysis based on 1,942 cases and

383 5,359 controls. PLoS One 2014;9:e110850.

384

385

386

EARLY ACCESS

387 Table 1 – Main characteristics of studies evaluating the association between exposure and haematological disorders.

Study	Haematologic cell lineage	Country	Gender	Age	Study design	Number of cases	Number of controls
Agriculture							
Benavente (2018) ³⁹	Lymphoid	Spain	M/F	>18	Case-Control	560	1845
Brown (1990) ¹⁷	Lymphoid	USA	M	>30	Case-Control	260	1245
Brown (1990) ¹⁷	Myeloid	USA	M	>30	Case-Control	257	1245
Brown (1990) ¹⁷	Not specified	USA	M	>30	Case-Control	578	1245
Ciccone (1993) ¹²	Myeloid	Italy	M/F	15-74	Case-Control	86	246
Costas (2015) ³⁵	Lymphoid	Europe	M/F	>18	Case-Control	2178	2457
Fan (2012) ³⁰	Lymphoid	China	M/F	>18	Case-Control	147	294
Goldberg (1990) ¹⁸	Myeloid	USA	-	28-88	Case-Control	52	52
Kokouva (2011) ¹³	Lymphoid	Greece	M/F	27-73	Case-Control	133	455
Kokouva (2011) ¹³	Myeloid	Greece	M/F	27-73	Case-Control	147	455
Kokouva (2011) ¹³	Not specified	Greece	M/F	27-73	Case-Control	428	455
LV (2011) ¹⁴	Myeloid	China	M/F	20-88	Case-Control	403	806
Mele (1994) ¹⁶	Lymphoid	Italy	M/F	>15	Case-Control	100	1161
Mele (1994) ¹⁶	Myeloid	Italy	M/F	>15	Case-Control	519	1161
Morton (2014) ³⁴	Lymphoid	Europe/North America/Australia	M/F	>18	Case-Control	17471	23096
Nisse (2001) ¹⁰	Myeloid	France	M/F	>18	Case-Control	204	204
Pekmezovic (2006) ⁸	Myeloid	Serbia Montenegro	M/F	18-85	Case-Control	80	160
Poynter (2017) ³⁸	Myeloid	USA	M/F	20-79	Case-Control	405	1348
Rigolin (1998) ¹¹	Myeloid	Italy	M/F	17-85	Case-Control	178	178

Slager (2014) ³¹	Lymphoid	Europe/North America/Australia	M/F	>18	Case-Control	1595	11602
Smedby (2014) ³³	Lymphoid	Europe/North America/Australia	M/F	>18	Case-Control	331	9720
Strom (2005) ⁹	Myeloid	USA	M/F	24-89	Case-Control	354	452
Wang (2014) ³²	Lymphoid	Europe/North America/Australia	M/F	>18	Case-Control	499	11490
West (1995) ¹⁵	Myeloid	UK	M/F	>18	Case-Control	400	400
Zhang (2019) ⁴¹	Lymphoid	China	M/F	>18	Case-Control	169	421
Chemical							
Costas (2015) ³⁵	Lymphoid	Europe	M/F	>18	Case-Control	2178	2457
Fan (2012) ³⁰	Lymphoid	China	M/F	>18	Case-Control	147	294
Hayes (1997) ²⁹	Lymphoid	China	M/F	>18	Cohort	90	1078
Hayes (1997) ²⁹	Myeloid	China	M/F	>18	Cohort	57	1078
Hayes (1997) ²⁹	Not specified	China	M/F	>18	Cohort	47	1078
Heavner (2015) ³⁷	Myeloid	USA	M/F	>42	Case-Control	54	472
Poynter (2017) ³⁸	Myeloid	USA	M/F	20-79	Case-Control	403	1344
Stenehjem (2015) ³⁶	Lymphoid	Norway	M/F	>18	Cohort	147	1661
Stenehjem (2015) ³⁶	Myeloid	Norway	M/F	>18	Cohort	31	1661
Stenehjem (2015) ³⁶	Not specified	Norway	M/F	>18	Cohort	112	1661
Zhang (2019) ⁴¹	Lymphoid	China	M/F	>18	Case-Control	169	421
Teras (2019) ⁹	Not specified	USA	M/F	>18	Cohort	2595	-
Indoor tanning							
Boffetta (2008) ²⁴	Lymphoid	Europe	M/F	>18	Case-Control	2028	2124
Grandin (2008) ²³	Lymphoid	France	M/F	>18	Case-Control	813	748

Hartge (2006) ²⁷	Lymphoid	USA	M/F	>18	Case-Control	551	462
Kelly (2010) ²¹	Lymphoid	USA	M/F	>18	Case-Control	140	139
Smedby (2005) ²⁸	Lymphoid	Sweden and Denmark	M/F	>18	Case-Control	3740	3178
Smedby (2005) ²⁸	Not specified	Sweden and Denmark	M/F	>18	Case-Control	3740	3178
Veierod (2010) ²²	Lymphoid	Norway	F	>18	Cohort	158	104953
Wang (2017) ¹⁹	Lymphoid	USA	F	20-79	Case-Control	1006	1038
Weihkopf (2007) ²⁶	Lymphoid	Germany	M/F	>18	Case-Control	710	710
Zhang (2007) ²⁵	Lymphoid	USA	F	>18	Cohort	601	717
Zhang (2013) ²⁰	Lymphoid	USA	F	>18	Cohort	4271	73358
Paint							
Mele (1994) ¹⁶	Lymphoid	Italy	M/F	>15	Case-Control	100	1161
Mele (1994) ¹⁶	Myeloid	Italy	M/F	>15	Case-Control	519	1161
Morton (2014) ³⁴	Lymphoid	Europe/North America/Australia	M/F	>18	Case-Control	17471	23096
Smedby (2014) ³³	Lymphoid	Europe/North America/Australia	M/F	>18	Case-Control	286	8150
Wang (2014) ³²	Lymphoid	Europe/North America/Australia	M/F	>18	Case-Control	454	9921
Zhang (2019) ⁴¹	Lymphoid	China	M/F	>18	Case-Control	169	421
Smoking							
Benavente (2018) ³⁹	Lymphoid	Spain	M/F	>18	Case-Control	560	1845
Ben-Eli (2019) ⁴²	Lymphoid	Spain	M/F	>18	Case-Control	280	211
Fan (2012) ³⁰	Lymphoid	China	M/F	>18	Case-Control	147	294
Mele (1994) ¹⁶	Lymphoid	Italy	M/F	>15	Case-Control	28	467
Mele (1994) ¹⁶	Myeloid	Italy	M/F	>15	Case-Control	249	467

388	Zhang (2019) ⁴¹	Lymphoid	China	M/F	>18	Case-Control	169	421
	(-) Not referred.							


EARLY ACCESS

389 Table 2 - Stratified pooled odds ratios of the relationship between agriculture, chemical
 390 and lifestyle exposures, and risk by cell-lineage type. The number of studies in each
 391 group is indicated. Note that some studies contribute with detailed information for more
 392 than one subgroup.

Exposure type/Cell-Lineage	No. studies	Effect size	CI low	CI high	I ²	P-value Cochran
Agriculture	20	OR 1.48	1.26	1.74	85%	< 0.01
Lymphoid	11	OR 1.38	1.11	1.72	91%	< 0.01
Myeloid	12	OR 1.79	1.28	2.50	78%	< 0.01
Haematological disorders not specified	2	OR 1.33	0.82	2.15	75%	= 0.05
Chemical	8	OR 1.62	1.15	2.28	80%	< 0.01
Lymphoid	5	OR 1.54	0.81	2.92	78%	< 0.01
Myeloid	4	OR 2.15	1.63	2.85	0%	< 0.53
Haematological disorders not specified	3	OR 1.40	0.90	2.16	61%	= 0.07
Lifestyle exposures						
Smoking	5	OR 1.14	0.82	1.59	80%	< 0.01
Lymphoid	5	OR 0.97	0.78	1.20	48%	= 0.11
Myeloid	1	OR 2.45	1.61	3.73	-	-
Paint	5	OR 1.12	0.99	1.27	0%	= 0.61
Lymphoid	5	OR 1.11	0.98	1.26	0%	= 0.51
Myeloid	1	OR 1.38	0.61	3.11	-	-
Indoor tanning	10	RR 1.01	0.80	1.27	0%	= 1.00
Lymphoid	10	RR 1.00	0.78	1.28	0%	= 0.29
Haematological disorders not specified	1	RR 1.09	0.61	1.95	-	-

393

394




395

396 Figure 1- Study selection procedure. Of the 665 abstracts retrieved from the PubMed
 397 searches, 595 were excluded. Most had no environmental risk factors or were focused
 398 on secondary cancers and non-hematologic cancers. From the 70 full-text articles
 399 considered, 35 works had no suitable data and only the remaining 35 were included in
 400 the meta-analysis.

401

402

403




404

405 Figure 2 - A forest plot illustrating risk estimates from studies included in the analysis of
 406 agriculture exposure and the risk of development of lymphoid/myeloid malignancies.

407

408



409

410 Figure 3 - A forest plot illustrating risk estimates from studies included in the analysis of
 411 chemical exposure and the risk of development of lymphoid/myeloid malignancies.

412

413

414

415

EARLY ACCESS